1 result for “Reaction Department”
-
Medical study · Medical research · 2021
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
…kg was selected as the recommended phase II dose. Seven patients (12%) reported infusion-related reactions. Treatment-related grade ≥3 treatment-emergent adverse events were pericardial effusion, colitis, infusion-related reaction, and pleural effusion (n=1 each…